Last reviewed · How we verify
APO-go
APO-go is a medication used to treat iron deficiency anemia.
APO-go is a medication used to treat iron deficiency anemia. Used for Treatment of iron deficiency anemia.
At a glance
| Generic name | APO-go |
|---|---|
| Also known as | amomorphine |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Iron replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
APO-go works by releasing iron from the drug, which is then absorbed by the body to treat iron deficiency anemia. It is a type of oral iron replacement therapy.
Approved indications
- Treatment of iron deficiency anemia
Common side effects
- Nausea
- Abdominal pain
- Constipation
- Diarrhea
- Vomiting
Key clinical trials
- A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) (PHASE3)
- Treating Severe Brain-injured Patients With Apomorphine (PHASE2)
- A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes (PHASE2)
- Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease (PHASE3)
- Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease (PHASE2)
- Apomorphine in Parkinson's Disease Patients With Visual Hallucinations (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |